Bicyclic thioketal cysteine-N-cyclocarboxylic acid anhydride as well as preparation method and application thereof
By designing the ROS-responsive polyamino acid formed by bicyclic thioketone cysteine-N-ring carboxylic acid anhydride, the problem of insufficient release of chemotherapy drugs in the tumor site is solved, and the efficient release of drugs in the tumor site is achieved, reducing the normal tissues Destructive effect.
Patent Information
- Application Number
- CN202411060230.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-05
AI Technical Summary
Existing chemotherapeutic drugs produce systemic toxicity during systemic treatment, and the drug release at the tumor site is not specific enough, resulting in damage to normal tissue.
A bicyclic thioketone cysteine-N-in-cyclic carboxylic acid anhydride was designed to form ROS-responsive polyamino acids through polymerization, encapsulate hydrophobic drugs, and responsively release in a high ROS environment at the tumor site.
The specific release of chemotherapy drugs in the tumor site is achieved, reducing the damage to normal tissues, and improving the stability and therapeutic effect of the drug.
Smart Images

Figure CN118978491A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic polymer compounds, and in particular relates to bicyclic thioketal cysteine-N-intra-ring carboxylic acid anhydride and a preparation method and application thereof. Background Art
[0002] In order to cope with the threat posed by cancer, a variety of treatment options are used clinically, including surgery, chemotherapy and radiotherapy. Although some emerging treatment options have emerged in recent years, such as targeted therapy, immunotherapy and gene therapy, chemotherapy is still one of the common methods for treating malignant tumors. Cisplatin (CDDP), doxorubicin (DOX) and paclitaxel (PTX) are the most widely used chemotherapy drugs in clinical practice. However, as a systemic treatment, chemotherapy drugs will diffuse to most organs and tissues in the body through blood circulation, which will inevitably produce systemic toxicity. The emergence of nano drug carriers improves the distribution of chemotherapy drugs in the human body and the metabolic kinetics of drugs, which helps to improve the therapeutic effect of chemotherapy drugs.
[0003] Tumor tissues are usually characterized by hypoxia, acidic pH, increased oxidative stress, high concentrations of glutathione (GSH), and overexpression of enzymes. The overproduction of reactive oxygen species (ROS) in tumor tissues is the result of the combined effects of multiple cancer-promoting events such as loss of tumor suppressor function and hypoxia-induced aerobic respiration. In addition, the higher the malignancy of the tumor, the higher its hypoxia. A variety of ROS-responsive smart nano drug delivery carriers designed and developed using the difference in ROS concentrations between normal physiological and pathological states have been used for antitumor drug delivery. For example, CN117551118A provides a polyamino acid containing phenylboronic acid, which realizes efficient loading of hydrophilic / hydrophobic small molecule drugs, polypeptide drugs, protein drugs, and nucleic acid drugs through the reactive oxygen response of the phenylboronic acid group, as well as their controlled release at the lesion site. CN114958008A provides a polyamino acid bonded glycosaminoglycan hydrogel responsive to active oxygen, whose polymer side chain contains thioether groups, which can respond to active oxygen and reduce the content of active oxygen. The glycosaminoglycan in the hydrogel has the function of actively eliminating excessive inflammatory response, thereby solving the problems of persistent inflammatory state of chronic wounds, drug tolerance and difficulty in healing. CN114409607A provides a polyamino acid containing thioether groups, which can self-assemble into nanoparticles with oxidation responsiveness in water, and the nanoparticles loaded with anticancer drugs can release the loaded drugs in the high active oxygen environment of the tumor, thereby killing tumor cells. In these schemes, the polyamino acid side chains all use thioether bonds or phenylboronic acid ester bonds as active oxygen responsive chemical bonds, and then release drugs at high active oxygen lesions to achieve selective treatment of diseases. However, these drugs are not stable enough under physiological conditions, and there are disadvantages such as drug leakage and difficulty in effectively protecting drugs. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a bicyclic thioketal cysteine-N-intracyclic carboxylic anhydride and a preparation method and application thereof in view of the deficiencies in the prior art. The bicyclic thioketal cysteine-N-intracyclic carboxylic anhydride is polymerized to obtain a ROS-responsive polyamino acid. The ROS-responsive polyamino acid can form stable micelles to encapsulate components such as hydrophobic drugs, imaging agents or dye molecules, protect the drugs before reaching the tumor site, and utilize the high ROS level in the tumor site for responsive release, thereby effectively solving the problem of specific release of chemotherapeutic drugs at the tumor site and reducing the destructive effect of drug leakage on normal tissues to a certain extent.
[0005] The present invention provides a bicyclic thioketal cysteine-N-intracyclic carboxylic anhydride, the structural formula of which is as follows:
[0006]
[0007] The present invention also provides a method for preparing the above-mentioned bicyclic thioketal cysteine-N-intracyclic carboxylic anhydride, the specific steps of which are as follows:
[0008] 1) L-cysteine hydrochloride and acetone are added to a dilute hydrochloric acid solution for condensation reaction, and post-treatment is performed to obtain cysteine (3,3'-(propane-2,2-diylbis(sulfinyl))bis(2-aminopropionic acid)) containing thioketal, the structure of which is
[0009] The formula is as follows:
[0010]
[0011] 2) adding the cysteine containing thioketal obtained in step 1) and triphosgene into a solvent for condensation reaction, and post-treating to obtain bicyclic thioketal cysteine-N-intra-ring carboxylic acid anhydride.
[0012] According to the above scheme, the mass ratio of L-cysteine hydrochloride to acetone in step 1) is 1:0.1-1.
[0013] According to the above scheme, the concentration of the dilute hydrochloric acid solution in step 1) is 0.5-12 mol / L, preferably 5-7 mol / L, and the mass volume ratio of the L-cysteine hydrochloride to the dilute hydrochloric acid solution is 1 g: 2-15 mL.
[0014] According to the above scheme, the condensation reaction conditions in step 1) are: under an inert atmosphere (nitrogen, helium or argon), react at 0-80°C for 3-36 hours, preferably at 25-40°C for 10-15 hours.
[0015] According to the above scheme, the mass ratio of the cysteine containing thioketal to triphosgene in step 2) is 1:0.4-6.0.
[0016] According to the above scheme, the solvent in step 2) is one of tetrahydrofuran (THF), dichloromethane, ethyl acetate, and N,N-dimethylformamide (DMF), preferably tetrahydrofuran or dichloromethane, and the mass volume ratio of the cysteine containing thioketal to the solvent is 0.05 to 0.5 g / mL.
[0017] According to the above scheme, the condensation reaction conditions in step 2) are: under an inert atmosphere, react at 5-70° C. for 1-10 h, preferably at 45-55° C. for 4-5 h.
[0018] The present invention also includes the application of the bicyclic thioketal cysteine-N-intra-ring carboxylic acid anhydride in the field of drug delivery carriers.
[0019] The present invention also includes a ROS-responsive polyamino acid prepared according to the above-mentioned bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride, and its structural formula is as follows:
[0020]
[0021] Where n is 18 to 460, m is 3 to 20, and y is 0 or 3 to 50;
[0022] R is selected from the following groups:
[0023] The present invention also includes a method for preparing the above-mentioned ROS-responsive polyamino acid, and the specific steps are as follows:
[0024] The bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride and the amino-terminated polyethylene glycol monomethyl ether are dissolved in a solvent, and copolymerized amino acid monomers are added as needed, and a ROS-responsive polyamino acid is obtained by polymerization reaction and purification.
[0025] According to the above scheme, the number average molecular weight (M n ) is 800~20000.
[0026] According to the above scheme, the copolymerized amino acid monomer is one of glutamic acid 5-benzyl ester N-carboxyl ring anhydride, L-phenylalanine-N-ring carboxylic anhydride, N6-benzyloxycarbonyl-L-lysine ring anhydride or methionine N-ring carboxylic anhydride, and its structure is shown below:
[0027]
[0028] According to the above scheme, the mass ratio of the bicyclic thioketal cysteine-N-intracyclic carboxylic anhydride to the amino-terminated polyethylene glycol monomethyl ether and the copolymerized amino acid monomer is 0.2-3.4:1:0.4-5.8.
[0029] According to the above scheme, the solvent is one of N,N-dimethylformamide, dimethyl sulfoxide (DMSO), chloroform, and tetrahydrofuran, preferably N,N-dimethylformamide or dimethyl sulfoxide. The mass volume ratio of the amino-terminated polyethylene glycol monomethyl ether to the solvent is 1g:5-30mL.
[0030] According to the above scheme, the polymerization reaction conditions are: under an inert atmosphere, react at 0-60°C for 24-120 hours, preferably at 25-30°C for 60-96 hours.
[0031] The present invention also provides the use of the above-mentioned ROS-responsive polyamino acid as a drug delivery carrier, wherein the polymer is assembled into nanoparticles, which are coated with hydrophobic drugs: such as anti-tumor drugs (including but not limited to doxorubicin, paclitaxel, etc.), anti-inflammatory drugs such as dexamethasone, as well as hydrophobic fluorescent probes, imaging agents, etc.
[0032] The specific application method is: dispersing the ROS-responsive polyamino acid and the hydrophobic drug in an organic solvent, adding water to obtain an emulsion, removing the organic solvent, freeze-drying to obtain nanoparticles, and storing them for later use.
[0033] The beneficial effects of the present invention are:
[0034] 1. The bicyclic thioketone cysteine-N-ring carboxylic anhydride containing thioketone groups designed and synthesized by the present invention contains two N-carboxyl ring anhydride units and a thioketone linking unit. The N-carboxyl ring anhydride unit can be self-polymerized, and can also be copolymerized with other amino acid ring anhydride monomers. Using terminal amino polyethylene glycol monomethyl ether as an initiator for polymerization, an amphiphilic block copolymer can be obtained, which can be self-assembled into a nanostructure and efficiently coated with hydrophobic drugs. The thioketone linking unit does not participate in the polymerization reaction, but can promote the cross-linking of the polyamino acid molecular chain, so that the nanostructure formed by self-assembly is very dense and stable, thereby protecting the coated drug from leakage during transportation and not causing damage to non-target organs. Since the thioketone structure is sensitive to ROS, once the drug carrier reaches the lesion site, the thioketone structure is immediately oxidized and broken, causing the disintegration of the carrier and the release of the drug molecules, and exerting its functional effect.
[0035] 2. The raw materials for preparing bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride of the present invention are L-cysteine hydrochloride, acetone and triphosgene, which are abundant in source, and the reaction steps are simple and easy to control. The by-products are basically gases, which are easy to separate and purify, and are convenient for mass production and popularization and application.
[0036] 3. The present invention uses the anhydride monomer of the amino acid ring N-carboxyl ring as the raw material to polymerize the ROS-responsive polyamino acid. The polymerization efficiency of such monomers is very high, and the only by-product is CO 2 , it is easy to separate, and the length of the hydrophilic and hydrophobic chain segments of the polymerization product can be adjusted by changing the dosage ratio of bicyclic thioketone cysteine-N-ring carboxylic anhydride and terminal amino polyethylene glycol monomethyl ether, thereby achieving polymer self-assembly and efficient drug encapsulation.
[0037] 4. The ROS-responsive polyamino acid prepared by the present invention has no restrictions on the types of drugs that can be encapsulated, and only needs to have a certain hydrophobicity. Therefore, it can be a small molecule anticancer drug such as paclitaxel or doxorubicin, a small molecule anti-inflammatory drug such as dexamethasone, or a fluorescent, phosphorescent, nuclear magnetic or radioactive agent for imaging and diagnosis purposes, which can realize multiple uses of one carrier.
[0038] 5. The method of using the ROS-responsive polyamino acid of the present invention to encapsulate drugs is to self-assemble in water, which can be achieved by simple room temperature dissolution, stirring evaporation at room temperature and freeze drying generally accepted by the pharmaceutical industry, which is easy to promote and apply. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 This is the hydrogen nuclear magnetic resonance spectrum of the cysteine containing thioketal prepared in Example 1 of the present invention;
[0040] Figure 2 This is the H NMR spectrum of the bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride prepared in Example 1;
[0041] Figure 3 The carbon NMR spectrum of the bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride prepared in Example 1;
[0042] Figure 4 is the hydrogen nuclear magnetic resonance spectrum of PEG-PCYT prepared in Example 2;
[0043] Figure 5 This is the hydrogen nuclear magnetic resonance spectrum of PEG-bP (CYT-co-BLG) prepared in Example 2;
[0044] Figure 6 The PEG-PCYT micelle dispersion in Example 5 and the 2 O 2 Comparison of H NMR spectra of aqueous solutions after reaction;
[0045] Figure 7 The PEG-bP (CYT-co-BLG) micellar dispersion in Example 5 and the H 2 O 2Comparison of H NMR spectra of aqueous solutions after reaction;
[0046] Figure 8 The PEG-PCYT micelle dispersion, PEG-bP (CYT-co-BLG) micelle dispersion and H 2 O 2 Comparison of DLS and TEM tests after aqueous solution reaction;
[0047] Fig. 9 The PEG-PCYT@DOX aqueous dispersion, PEG-bP(CYT-co-BLG)@DOX aqueous dispersion and H 2 O 2 Comparison of DLS and TEM tests after aqueous solution reaction;
[0048] Fig.10 The PEG-PCYT micelle aqueous dispersion containing Nile Red in Example 8 was dissolved in PBS buffer containing 50 mM MH 2 O 2 PBS buffer and 100 mM HO 2 O 2 Comparison of drug release curves in PBS buffer;
[0049] Fig.11 The photographs of PEG-PCYT@DOX micelles being taken up by cells at 2 h, 4 h and 6 h observed by inverted fluorescence microscopy in Example 9;
[0050] Fig.12 It is a comparison chart of cell survival rates of 4T1 and L929 cells in different concentrations of PEG-PCYT micelle dispersion and PEG-bP (CYT-co-BLG) micelle dispersion in Example 10;
[0051] Fig.13 This is a test graph of the killing effect of PEG-PCYT@DOX, PEG-bP(CYT-co-BLG)@DOX and pure doxorubicin on 4T1 cells in Example 11. DETAILED DESCRIPTION
[0052] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail below using embodiments in conjunction with the accompanying drawings.
[0053] Example 1
[0054] Synthesis of bicyclic thioketal cysteine-N-intracyclic carboxylic anhydride (CysTK NCA):
[0055] The synthetic route and typical reaction conditions are as follows:
[0056]
[0057] The synthesis process is as follows:
[0058] 1) L-cysteine hydrochloride (2 g, 12.7 mmol) was dissolved in 10 mL of dilute hydrochloric acid solution (6 mol / L), and acetone (1.48 g, 25.4 mmol) was added. The mixture was stirred at 30 °C for 12 h under nitrogen atmosphere, and then the solvent was removed by rotary evaporation. The mixture was washed with dilute hydrochloric acid solution, and then pure water was added to recrystallize at 95 °C for three times. The mixture was dried to obtain a white crystalline product of cysteine containing thioketal (CysTK, 1.39 g, yield: 71.53%). Step 1) was repeated for several times to collect more product.
[0059] 2) Cysteine containing thioketal (2.8 g, 10 mmol) was suspended in 30 mL of anhydrous tetrahydrofuran. Under a nitrogen atmosphere, triphosgene (1.24 g, 4.17 mmol) was added to the reaction system in batches and reacted at 55° C. for 4 h. After the reaction was completed, the unreacted raw materials were filtered out, and the filtrate was precipitated in n-hexane and filtered. The product was dissolved in 500 mL of ethyl acetate and washed with ice-saturated sodium carbonate solution and pure water (10 mL×3) in turn, dried over anhydrous magnesium sulfate, filtered, and the solvent was removed under reduced pressure to obtain a crude product. The crude product was recrystallized three times in a mixed solvent of ethyl acetate and n-hexane in a volume ratio of 4:1 to obtain 0.43 g of a light yellow product (CysTK NCA, yield 13%).
[0060] Figure 1 This is the hydrogen nuclear magnetic resonance spectrum of the cysteine containing thioketal synthesized in step 1) of this example.
[0061] Figure 2 and Figure 3 The hydrogen nuclear magnetic resonance spectrum and carbon nuclear magnetic resonance spectrum of the bicyclic thioketal cysteine-N-intracyclic carboxylic anhydride prepared in this example are respectively shown. The characteristic peak of the methyl group on the thioketal appears in the spectrum, and the chemical shift and integrated intensity at each proton are analyzed, proving that the bicyclic thioketal cysteine-N-intracyclic carboxylic anhydride has been synthesized.
[0062] Example 2
[0063] Synthesis of ROS-responsive polyamino acid polymer PEG-PCYT and copolymer PEG-bP (CYT-co-BLG):
[0064] The synthetic route and typical reaction conditions are as follows:
[0065]
[0066] The synthesis process is as follows:
[0067] Weigh 0.5 g of amino-terminated polyethylene glycol monomethyl ether (PEG-NH 2 , 0.1mmol) in a polymerization bottle, remove water with toluene azeotropically for 2h, cool to 30-40°C, then add the bicyclic thioketal cysteine-N-intracyclic carboxylic anhydride (CysTK NCA, 0.167g, 0.5mmol) prepared in Example 1, add 10mL DMF as solvent under nitrogen protection, stir and react at room temperature for 72h, precipitate the reactant in 0°C anhydrous ether, filter to obtain a white solid, and vacuum dry to obtain 0.61g of a white product PEG 113 -PCYT 5 (denoted as PEG-PCYT, yield 90.7%).
[0068] Weigh 0.5 g of amino-terminated polyethylene glycol monomethyl ether (PEG-NH 2 , 0.1mmol) in a polymerization bottle, remove water with toluene azeotropically for 2h, cool to 30-40°C, then add 0.526g of 5-benzyl glutamic acid N-carboxyl ring anhydride (BLG NCA, 2mmol) monomer and 0.167g of CysTK NCA (0.5mmol) monomer prepared in Example 1, add 12mL N,N-dimethylformamide as solvent under nitrogen protection, stir and react at room temperature (25°C) for 72h, precipitate the reactant in ice anhydrous ether, filter to obtain a white solid, and vacuum dry to obtain 1.09g of white product PEG 113 -bP(CYT 5- co-BLG 20 ) (denoted as PEG-bP(CYT-co-BLG), yield 91.6%).
[0069] The nuclear magnetic resonance hydrogen spectrum of PEG-PCYT synthesized in this example is as follows Figure 4 shown.
[0070] The nuclear magnetic resonance hydrogen spectrum of PEG-bP (CYT-co-BLG) synthesized in this example is as follows Figure 5 shown.
[0071] The amount of raw materials used in this example was adjusted, and other conditions remained unchanged to obtain products with different polymerization degrees. The amount of raw materials used and the products with different polymerization degrees are shown in Table 1 below.
[0072] Table 1
[0073]
[0074] Example 3
[0075] Synthesis of copolymer PEG-bP(CYT-co-Met):
[0076] The synthetic route and typical reaction conditions are as follows:
[0077]
[0078] The synthesis process is as follows:
[0079] Weigh 0.5 g PEG-NH 2 (0.1mmol) was added to a polymerization bottle, and water was removed by azeotropic distillation with toluene for 2h, and the mixture was cooled to 30-40°C. Then, 0.35g of L-methionine-N-intracyclic carboxylic anhydride (L-Met NCA, 2mmol) monomer and 0.167g of CysTK NCA (0.5mmol) monomer prepared in Example 1 were added. Under nitrogen protection, 15mL of dimethyl sulfoxide was added as solvent, and the reaction was stirred at 30°C for 80h. The reactants were precipitated in ice anhydrous ether, filtered to obtain a white solid, and vacuum dried to obtain 0.94g of a white product PEG-bP (CYT-co-Met) (yield 92.4%).
[0080] Example 4
[0081] Synthesis of copolymer PEG-bP(CYT-co-Lys):
[0082] The synthetic route and typical reaction conditions are as follows:
[0083]
[0084] The synthesis process is as follows:
[0085] Weigh 0.5 g PEG-NH 2 (0.1mmol) was added to a polymerization bottle, and water was removed by azeotropic distillation with toluene for 2h, and the mixture was cooled to 30-40°C. Then, 0.344g of N6-benzyloxycarbonyl-L-lysine cyclic anhydride (Lys NCA, 2mmol) monomer and 0.167g of CysTK NCA (0.5mmol) monomer prepared in Example 1 were added. Under nitrogen protection, 50mL of chloroform was added as solvent, and the reaction was stirred at 27°C for 96h. The reactant was precipitated in ice anhydrous ether, filtered to obtain a white solid, and vacuum dried to obtain 0.89g of a white product PEG-bP (CYT-co-Lys) (yield 88.1%).
[0086] Example 5
[0087] Preparation of ROS-responsive polyamino acid micelles:
[0088] The polymer was self-assembled into micelles by the oil-in-water (O / W) emulsion method: 10 mg of the PEG-PCYT prepared in Example 2 was dispersed in 100 μL of chloroform, added dropwise to 4 mL of ultrapure water and ultrasonically dispersed for 15 min to form an emulsion, the chloroform was completely evaporated at room temperature, centrifuged, filtered through a microporous filter membrane (pore size: 0.225 μm), and then diluted to obtain a polymer PEG-PCYT micelle dispersion (1 mg / mL).
[0089] The polymer PEG-bP (CYT-co-BLG) prepared in Example 2 was used as a raw material, and the above method was used to prepare a polymer PEG-bP (CYT-co-BLG) micelle dispersion (1 mg / mL).
[0090] ROS response performance test:
[0091] To 1 mL of the two micelle dispersions prepared above, 100 μL of 10 mM H 2 O 2 After stirring for 24 h, the two micellar dispersions and the H 2 O 2 The comparison of H NMR spectra of aqueous solution after reaction is shown in Figure 6 and Figure 7 As shown, it can be seen that the nuclear magnetic resonance hydrogen spectrum after the reaction did not detect the characteristic peak of the proton at the methyl group on the thioketal, proving that the chemical bond was broken at the thioketal.
[0092] Dynamic light scattering (DLS) was used to measure the two micellar dispersions and the 2 O 2 The micelle size changes after the aqueous solution reaction, and the morphology changes of the micelles before and after the reaction were tested by transmission electron microscopy (TEM). The test figure is as follows Figure 8 As shown in Figure 2, the average particle size of PEG-PCYT micelles is 57.51±5.28nm, and the average particle size of PEG-bP(CYT-co-BLG) micelles is 90.54±5.87nm, which is similar to that of H 2 O 2 After the reaction, the average particle sizes of the two micelles were 751±88.71nm and 652±51.58nm, respectively, indicating that the two micelles were 2 O 2 After stirring at room temperature, the micelle size increased significantly, proving that both polymers have good ROS response characteristics. Figure 8 As can be seen from the inset, both micelles are spherical in morphology, but unlike H 2 O 2 After the reaction, the spherical morphology of the micelles collapsed.
[0093] Example 6
[0094] Preparation of ROS-responsive polyamino acid micelles encapsulating doxorubicin (DOX):
[0095] 10 mg of PEG-PCYT prepared in Example 2 was dissolved in 100 μL of chloroform to obtain a PEG-PCYT dispersion. 12 mg of doxorubicin hydrochloride was dissolved in 500 μL of dimethyl sulfoxide, and triethylamine was added to remove hydrochloric acid. 50 μL of the doxorubicin solution from which hydrochloric acid had been removed was mixed with 100 μL of the PEG-PCYT dispersion and then added to 4 mL of ultrapure water for ultrasonic dispersion for 15 min to form an emulsion. The organic solvent was completely evaporated at room temperature, and the solvent was removed by dialysis (MWCO 3.5 kDa). After centrifugation (3500 rpm), filtration and dilution, a fluorescently labeled micelle PEG-PCYT@DOX aqueous dispersion (1 mg / mL) was obtained.
[0096] Polymer PEG with different polymerization degrees prepared in Example 2 113 -PCYT 10 PEG 113 -bP(CYT 5 -co-BLG 20 ), PEG 113 -bP(CYT 10 -co-BLG 20 ) were used as raw materials, and different drug-loaded micelle aqueous dispersions (1 mg / mL) were prepared using the above method.
[0097] Determination of drug loading capacity (DLC) and drug loading efficiency (DLE): The DOX content in the ROS-responsive polyamino acid micelles encapsulating doxorubicin (DOX) was determined by measuring the doxorubicin absorption value at 585 nm using a UV-visible spectrophotometer, and the drug loading capacity (DLC) and drug loading efficiency (DLE) were calculated using the formula.
[0098]
[0099] The performance test results of the above-mentioned ROS-responsive polyamino acid micelles encapsulating doxorubicin (DOX) are shown in Table 2.
[0100] Table 2
[0101]
[0102] The above test results show that the drug loading amount and drug loading efficiency of the material are correlated to a certain extent with the degree of polymerization of bicyclic thioketal cysteine-N-ring carboxylic anhydride. The drug loading efficiency in the drug-loaded micelles is above 70%, indicating that the micelles have good drug loading capacity.
[0103] Dynamic light scattering was used to test the particle size changes of the two dispersions prepared in this example and the blank micelle dispersions without drug coating (the two micelle dispersions prepared in Example 5), and transmission electron microscopy was used to test the morphology changes before and after the micelle reaction. The test graph is as follows: Fig. 9 As shown, it can be seen that due to hydrophobic interaction, the micelle particle size after encapsulating the drug is significantly increased relative to the blank micelle, and the PDI value is reduced. This is mainly because doxorubicin exists inside the micelle, and the micelle particle size is increased based on hydrophobic interaction.
[0104] Example 7
[0105] Preparation of ROS-responsive polyamino acid micelles encapsulating dexamethasone (DEX):
[0106] 15 mg of PEG-PCYT prepared in Example 2 was dissolved in 150 μL of chloroform to obtain a PEG-PCYT dispersion, 1 mg of DEX was dissolved in 100 μL of dimethyl sulfoxide to obtain a DEX dispersion, 50 μL of DEX dispersion was mixed with 150 μL of PEG-PCYT dispersion and added to 4 mL of ultrapure water for 15 min of ultrasound to form an emulsion, the organic solvent was completely evaporated at room temperature, the solvent was removed by dialysis (MWCO 3.5 kDa), and the fluorescently labeled micelle PEG-PCYT@DEX aqueous dispersion (1 mg / mL) was obtained by dilution after centrifugation (3500 rpm).
[0107] The polymer PEG-bP (CYT-co-BLG) prepared in Example 2 was used as a raw material, and the above method was used to prepare a PEG-bP (CYT-co-BLG) @ DEX aqueous dispersion (1 mg / mL).
[0108] Example 8
[0109] Drug release performance test:
[0110] Nile red was encapsulated in micelles as a model drug and exposed to different concentrations of H 2 O 2 The solution was co-incubated to simulate the drug release behavior of responsive micelles. The same method as in Example 6 was used to prepare a PEG-PCYT micelle aqueous dispersion containing Nile red (Nile red concentration 0.1 mg / mL). 100 μL of the micelle aqueous dispersion containing Nile red was added to 2 mL PBS buffer (pH 7.0), 2 mL containing 50 mM H 2 O 2 2 mL of PBS buffer containing 100 mM HO 2 O 2Incubate at 37°C in PBS buffer. Set up three parallel control samples for each experimental group. Nile red in micelles has fluorescence, with a maximum emission peak at 570nm. The released Nile red in aqueous solution has no fluorescence. Samples were taken at 0h, 3h, 6h, 12h, 24h, 36h, 48h, 72h, 96h and 120h, and the emission peak of Nile red at 570nm was tested by fluorescence spectrometer. The excitation and emission slit widths were set to 5nm. The cumulative release of Nile red was calculated as follows:
[0111]
[0112] Among them, FI 0 is the fluorescence intensity at the beginning of the experimental group, FI t The fluorescence intensity at the time of measurement was for the experimental group.
[0113] In this example, the micellar aqueous dispersions encapsulating Nile red were prepared in PBS buffer, 50 mM H 2 O 2 PBS buffer and 100 mM HO 2 O 2 The drug release curve during incubation in PBS buffer is shown in Fig.10 As shown in the figure, Control means incubation in PBS buffer. It can be seen that the drug release amount is related to H 2 O 2 The concentration is directly proportional to the addition of H 2 O 2 The drug-loaded micelles released the drug continuously within 120 h, achieving the purpose of sustained drug release and continuous treatment, while only about 5% of the drug was released in the Control group, indicating that the micelles had good sealing properties and did not leak.
[0114] Example 9
[0115] In vitro cell uptake capacity test:
[0116] 4T1 cells (mouse breast cancer cells) were counted and expressed as approximately 2×10 5 The cells were seeded at a density of 100 / well in a 6-well plate and incubated at 37°C and 5% CO 2 The cells were cultured for 24 h under the environment of 4T1 cells, and then incubated with the aqueous dispersion of PEG-PCYT@DOX micelles encapsulating doxorubicin described in Example 6 (doxorubicin concentration was 10 μg / mL) for 2 h, 4 h, and 6 h. The culture medium was then removed, and the cells were washed three times with PBS to remove the uninternalized micelles. The cells were fixed with 4% paraformaldehyde at room temperature for 30 min, and the uptake behavior of PEG-PCYT@DOX micelles by 4T1 cells was observed under an inverted fluorescence microscope. Fig.11The picture shown is the photos of the fluorescent labeled micelles PEG-PCYT@DOX being taken up by cells at 2h, 4h and 6h observed by inverted fluorescence microscope. Bright Field is the bright field image, Fluorescence is the fluorescence image, Merged is the bright field and fluorescence superposition image. The red fluorescence intensity in the cells was observed to gradually increase at 2h, 4h and 6h, indicating that the micelles were continuously internalized by the cells with the extension of time, proving that PEG-PCYT micelles can be continuously taken up by cells as drug delivery carriers.
[0117] Example 10
[0118] In vitro cell safety testing:
[0119] The cytotoxicity of the micelles to 4T1 and L929 cells was detected by the methylthiazolium tetrazolium (MTT) assay.
[0120] 4T1 or L929 cells were grown at a rate of approximately 8 × 10 3 The cells were seeded at a density of 1000 cells / well in a 96-well plate and incubated at 37°C with 5% CO 2 The cells were cultured in a 4% sodium-ion battery atmosphere. When the cell confluence reached about 80%, PEG-PCYT micelle dispersion and PEG-bP (CYT-co-BLG) micelle dispersion (prepared by the method of Example 5 and diluted with pure water to the required concentration) were added in a concentration gradient of 1000 μg / mL, 200 μg / mL, 40 μg / mL, 8 μg / mL, 1.6 μg / mL and 0.32 μg / mL, respectively. After incubation for 24 hours, the culture medium was removed, and 110 μL of culture medium containing 10 μL of 5 mg / mL MTT detection solution was added to each well. After incubation at 37°C for 4 hours, 100 μL of DMSO was added to each well, and the cells were placed in an incubator and incubated for 2 hours to dissolve the generated formazan crystals. The absorbance at 570 nm was measured by an ELISA instrument to calculate the cell survival rate.
[0121]
[0122] Where N s 、N c 、N b The absorbances of the sample well, control well (without micelle solution), and blank well are shown in Figure 2. Fig.12 As shown, Fig.12 a is a comparison of cell survival rates of L929 cells and 4T1 cells in PEG-PCYT micelle dispersions of different concentrations. Fig.12b is a comparison chart of the cell survival rates of L929 cells and 4T1 cells in different concentrations of PEG-bP (CYT-co-BLG) micelle dispersions. At the micelle solution concentration of 0.32 to 1000 μg / mL, the cell survival rates of both 4T1 and L929 cell lines in the two micelle solutions were above 90%, indicating that the micelles have less cytotoxicity and have good cell safety as in vivo drug delivery carriers.
[0123] Embodiment 11
[0124] In vitro cell killing test:
[0125] 4T1 cells were approximately 8×10 3 The cells were seeded at a density of 1000 cells / well in a 96-well plate and incubated at 37°C with 5% CO 2 The cells were cultured in a gas atmosphere. When the cell confluence reached about 80%, the cells were treated with PEG-PCYT@DOX and PEG-bP(CYT-co-BLG)@DOX aqueous dispersions (the aqueous dispersions were prepared using the method of Example 6 and diluted with water to the required concentration) with drug DOX concentrations of 160μg / mL, 80μg / mL, 40μg / mL, 20μg / mL, 10μg / mL and 5μg / mL, respectively. At the same time, the cells were treated with an aqueous solution of free DOX (Free DOX) of the same equivalent concentration as a control. The cells were incubated in a cell culture incubator for 24 hours, the culture medium was removed, and 110μL of culture medium containing 10μL of 5mg / mL MTT detection solution was added to each well. After 4 hours, 100μL of DMSO was added to each well, and the cells were incubated in an incubator for 2 hours to dissolve the produced formazan crystals. The absorbance value at 570nm was measured using an enzyme marker to determine cell viability. The experimental results are shown in the figure. Fig.13 As shown, it can be seen that both polymer drug-loaded micelles have good killing effects on 4T1 cells, and are better than free DOX at the same equivalent concentration, and the killing effect on cells shows a certain correlation with the concentration within the tested concentration range.
Claims
1. A bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride, characterized in that: Its structural formula is as follows:
2. The method for preparing the bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride according to claim 1, characterized in that: The specific steps are as follows: 1) L-cysteine hydrochloride and acetone are added to a dilute hydrochloric acid solution for condensation reaction, and post-processed to obtain cysteine containing thioketal, the structural formula of which is shown below: 2) adding the cysteine containing thioketal obtained in step 1) and triphosgene into a solvent for condensation reaction, and post-treating to obtain bicyclic thioketal cysteine-N-intra-ring carboxylic acid anhydride.
3. The method for preparing the bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride according to claim 2, characterized in that: The mass ratio of L-cysteine hydrochloride to acetone in step 1) is 1:0.1-1; the concentration of the dilute hydrochloric acid solution in step 1) is 0.5-12 mol / L, and the mass volume ratio of L-cysteine hydrochloride to the dilute hydrochloric acid solution is 1 g:2-15 mL; the condensation reaction conditions in step 1) are: reacting at 0-80° C. for 3-36 hours under an inert atmosphere.
4. The method for preparing the bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride according to claim 2, characterized in that: In step 2), the mass ratio of the cysteine containing the thioketal to triphosgene is 1:0.4-6.0; in step 2), the solvent is one of tetrahydrofuran, dichloromethane, ethyl acetate, and N,N-dimethylformamide, and the mass volume ratio of the cysteine containing the thioketal to the solvent is 0.05-0.5 g / mL; in step 2), the condensation reaction conditions are: reacting at 5-70° C. for 1-10 hours under an inert atmosphere.
5. Use of the bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride according to claim 1 in the field of drug delivery carriers.
6. A ROS-responsive polyamino acid prepared based on the bicyclic thioketal cysteine-N-intra-ring carboxylic anhydride according to claim 1, characterized in that: Its structural formula is as follows: Where n is 18 to 460, m is 3 to 20, and y is 0 or 3 to 50; R is selected from the following groups:
7. The method for preparing the ROS-responsive polyamino acid according to claim 6, characterized in that: The specific steps are as follows: dissolving the above-mentioned bicyclic thioketal cysteine-N-intra-ring carboxylic acid anhydride and terminal amino group polyethylene glycol monomethyl ether in a solvent, adding copolymerized amino acid monomers as needed, and obtaining ROS-responsive polyamino acid through polymerization reaction and purification.
8. The method for preparing a ROS-responsive polyamino acid according to claim 7, characterized in that: The number average molecular weight of the amino-terminated polyethylene glycol monomethyl ether is 800-20000; the copolymerized amino acid monomer is one of glutamic acid 5-benzyl ester N-carboxyl ring anhydride, L-phenylalanine-N-ring carboxylic anhydride, N6-benzyloxycarbonyl-L-lysine ring anhydride or methionine N-ring carboxylic anhydride; the mass ratio of the bicyclic thioketal cysteine-N-ring carboxylic anhydride to the amino-terminated polyethylene glycol monomethyl ether and the copolymerized amino acid monomer is 0.2-3.4:1:0.4-5.8; the polymerization reaction conditions are: reacting at 0-60°C for 24-120h under an inert atmosphere.
9. Use of the ROS-responsive polyamino acid according to claim 6 as a drug delivery carrier, characterized in that: The ROS-responsive polyamino acids are assembled into nanoparticles, in which hydrophobic drugs are encapsulated.
10. The use of the ROS-responsive polyamino acid as a drug delivery carrier according to claim 9, characterized in that: The specific application method is: dispersing the ROS-responsive polyamino acid and the hydrophobic drug in an organic solvent, adding water to obtain an emulsion, removing the organic solvent, freeze-drying to obtain nanoparticles, and storing them for later use.
Citation Information
Patent Citations
Thioether group-containing N-carboxyl intracyclic anhydride as well as preparation method and application thereof
CN114409607A
